170 related articles for article (PubMed ID: 37148422)
1. Persistent SARS-CoV-2 PCR Positivity Despite Anti-viral Treatment in Immunodeficient Patients.
Chan M; Linn MMN; O'Hagan T; Guerra-Assunção JA; Lackenby A; Workman S; Dacre A; Burns SO; Breuer J; Hart J; Tadros S; Lowe DM
J Clin Immunol; 2023 Aug; 43(6):1083-1092. PubMed ID: 37148422
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
[TBL] [Abstract][Full Text] [Related]
3. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
[TBL] [Abstract][Full Text] [Related]
5. Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review.
Hettle D; Hutchings S; Muir P; Moran E;
Clin Infect Pract; 2022 Nov; 16():100210. PubMed ID: 36405361
[TBL] [Abstract][Full Text] [Related]
6. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
7. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
8. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.
Ikegami S; Benirschke R; Flanagan T; Tanna N; Klein T; Elue R; Debosz P; Mallek J; Wright G; Guariglia P; Kang J; Gniadek TJ
Transfusion; 2020 Dec; 60(12):2962-2968. PubMed ID: 32840002
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of Viral Clearance and Antibody Production Across Age Groups in Children with Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Bahar B; Jacquot C; Mo YD; DeBiasi RL; Campos J; Delaney M
J Pediatr; 2020 Dec; 227():31-37.e1. PubMed ID: 32891640
[TBL] [Abstract][Full Text] [Related]
10. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir.
Martin-Blondel G; Marcelin AG; Soulié C; Kaisaridi S; Lusivika-Nzinga C; Zafilaza K; Dorival C; Nailler L; Boston A; Ronchetti AM; Melenotte C; Cabié A; Choquet C; Trinh-Duc A; Lacombe K; Gaube G; Coustillères F; Pourcher V; Martellosio JP; Peiffer-Smadja N; Chauveau M; Housset P; Piroth L; Devaux M; Pialoux G; Martin A; Dubee V; Frey J; Le Bot A; Cazanave C; Petua P; Liblau R; Carrat F; Yordanov Y
Clin Microbiol Infect; 2023 Apr; 29(4):543.e5-543.e9. PubMed ID: 36586513
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
12. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study.
Fountain-Jones NM; Vanhaeften R; Williamson J; Maskell J; Chua IJ; Charleston M; Cooley L
Lancet Microbe; 2024 May; 5(5):e452-e458. PubMed ID: 38527471
[TBL] [Abstract][Full Text] [Related]
13. Persistent Fever and Positive PCR 90 Days Post-SARS-CoV-2 Infection in a Rituximab-Treated Patient: A Case of Late Antiviral Treatment.
Ertesvåg NU; Sakkestad ST; Zhou F; Hoff I; Kristiansen T; Jonassen TM; Follesø E; Brokstad KA; Dyrhovden R; Mohn KG
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016378
[No Abstract] [Full Text] [Related]
14. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses.
Vibholm LK; Nielsen SSF; Pahus MH; Frattari GS; Olesen R; Andersen R; Monrad I; Andersen AHF; Thomsen MM; Konrad CV; Andersen SD; Højen JF; Gunst JD; Østergaard L; Søgaard OS; Schleimann MH; Tolstrup M
EBioMedicine; 2021 Feb; 64():103230. PubMed ID: 33530000
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
[TBL] [Abstract][Full Text] [Related]
17. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
20. Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study.
De Vito A; Moi G; Saderi L; Puci MV; Colpani A; Firino L; Puggioni A; Uzzau S; Babudieri S; Sotgiu G; Madeddu G
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
